60 Degrees Pharmaceuticals, Inc. (SXTP) stock price, financials & research

Regular session · ET · Market data may be delayed.

GoAI snapshot

Jul 10, 2026

34/ 100

GoAI Score

Sell

Valuation

49

Fair Value

Sentiment

55

Mixed

Risk

85

Extreme Risk

Momentum

27

Weakening

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

Company profile

Industry: Biotechnology
Sector: Healthcare
Headquarters: US

Market position

Day range

Current $0.9654

$0.91$0.98

52-week range

Current $0.9654

$0.84$8.62

Open: $0.96
Previous close: $0.9725
Volume: 41.07K
Market cap: 3.4M USD
50-day average: $1.0984; -12.11% below average
200-day average: $1.8847; -48.78% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

P/E (TTM): -0.16×
P/B (TTM): 0.98×
P/S (TTM): 3.06×
Dividend yield: 0.00%

Profitability & efficiency

Gross margin: 19.42%
Operating margin: -774.90%
Net margin: -730.23%

Financial health

Debt / equity: 0.06×
Altman Z-score: -21.31
Piotroski F-score: 2 of 9

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin

Income trends

Revenue

1.01M USD+65.49%

Operating income

−7.76M USD+20.14%

Net income

−7.37M USD+7.28%

Financial statements: Income statement
Metric (USD)	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue	1.01M USD	607.57K USD	253.57K USD	223.21K USD	1.16M USD
Cost of goods sold	781.7K USD	384.77K USD	474.55K USD	432.37K USD	850.74K USD
Gross profit	223.78K USD	222.81K USD	−220.98K USD	−209.16K USD	309.6K USD
Research and development	2.11M USD	4.99M USD	691.77K USD	525.56K USD	5.51M USD
Selling, general, and administrative	6.28M USD	5.02M USD	4.24M USD	1.3M USD	1.12M USD
Operating expenses	7.98M USD	9.94M USD	4.93M USD	1.54M USD	1.43M USD
Interest expense	7.81K USD	7.91K USD	2.29M USD	3.99M USD	3.17M USD
Depreciation and amortization	82.87K USD	63.75K USD	100.37K USD	78.79K USD	71.79K USD
Operating income	−7.76M USD	−9.71M USD	−5.15M USD	−1.75M USD	−1.12M USD
Net income	−7.37M USD	−7.95M USD	−3.77M USD	−6.18M USD	−4.25M USD

Company facts updated Oct 10, 2026.

Earnings

EPS beat rate: 18%; 2 beats, 9 misses, 0 met estimates
Average EPS surprise: -20.62%; 11 comparable reports
Latest EPS result: -0.9; Estimate -0.74 · Miss by 22.45%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate

SXTP news

globenewswire.comOct 6, 2026

60 Degrees Pharmaceuticals Plans January 2027 Hospitalized Babesiosis Data Readout; Will Seek Pre-sNDA Meeting with FDA

After a scheduled interim analysis of the severe babesiosis study on October 1, 2026, the DSMB recommended completing the study with the originally planned number of patients (N=33); the study remains blinded As of the…

Read source

globenewswire.comOct 1, 2026

60 Degrees Pharmaceuticals Announces Date for Hospitalized Babesiosis Study Interim Data Release and Key Opinion Leader Webinar

Interim analysis results from clinical study evaluating tafenoquine in severe babesiosis ( NCT06207370 ) to be disclosed on October 6, 2026. Key Opinion Leader investor webinar scheduled for October 6, 2026, featuring…

Read source

defenseworld.netSep 16, 2026

Reviewing Innoviva (NASDAQ:INVA) and 60 Degrees Pharmaceuticals (NASDAQ:SXTP)

Innoviva (NASDAQ: INVA - Get Free Report) and 60 Degrees Pharmaceuticals (NASDAQ: SXTP - Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based…

Read source

globenewswire.comSep 3, 2026

60 Degrees Pharmaceuticals Announces Participation in H.C. Wainwright 28th Annual Global Investment Conference

60 Degrees Pharma (Nasdaq: SXTP) will present on demand at H.C. Wainwright beginning Sept. 11 and hold 1 x 1 investor meetings Sept. 14–16 in New York.

Read source

globenewswire.comAug 14, 2026

60 Degrees Pharmaceuticals Announces Second Quarter 2026 Results

WASHINGTON, Aug. 14, 2026 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (the “Company”), a pharmaceutical company focused on developing new medicines for vector-borne diseases, reported today…

Read source

globenewswire.comJul 30, 2026

60 Degrees Pharmaceuticals, Inc. Announces Private Placement Priced At-the-Market Under Nasdaq Rules

WASHINGTON, July 30, 2026 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP, SXTPW) (“60 Degrees” or the “Company”), a pharmaceutical company that develops and commercializes new medicines for…

Read source

Corporate actions

Corporate action history

Action	Effective date	Details	Record date	Payment date
Stock split	Jan 20, 2026	1:4	—	—
Stock split	Feb 24, 2025	1:5	—	—
Stock split	Aug 12, 2024	1:12	—	—

Stock split

Effective Jan 20, 2026

1:4

Stock split

Effective Feb 24, 2025

1:5

Stock split

Effective Aug 12, 2024

1:12

SXTP peers

AMGN

Amgen Inc.

$414.87

+1.82%

GILD

Gilead Sciences, Inc.

$151.17

+2.77%

ISRG

Intuitive Surgical, Inc.

$423.96

+2.06%

VRTX

Vertex Pharmaceuticals Incorporated

$510.08

+1.36%

SNY

Sanofi

$40.07

-0.40%

MRNA

Moderna, Inc.

$225

+14.21%

60 Degrees Pharmaceuticals, Inc.

SXTP company overview

60 Degrees Pharmaceuticals, Inc.

SXTP company overview

GoAI snapshot

Company profile

Market position

Financials

Financial snapshot

Valuation & yield

Profitability & efficiency

Financial health

Financial statements

Margin trends

Income trends

Earnings

EPS: actual versus estimate

Revenue: actual versus estimate

SXTP news

60 Degrees Pharmaceuticals Plans January 2027 Hospitalized Babesiosis Data Readout; Will Seek Pre-sNDA Meeting with FDA

60 Degrees Pharmaceuticals Announces Date for Hospitalized Babesiosis Study Interim Data Release and Key Opinion Leader Webinar

Reviewing Innoviva (NASDAQ:INVA) and 60 Degrees Pharmaceuticals (NASDAQ:SXTP)

60 Degrees Pharmaceuticals Announces Participation in H.C. Wainwright 28th Annual Global Investment Conference

60 Degrees Pharmaceuticals Announces Second Quarter 2026 Results

60 Degrees Pharmaceuticals, Inc. Announces Private Placement Priced At-the-Market Under Nasdaq Rules

Corporate actions

Corporate action history

SXTP peers

Continue in GoAI

SXTP company overview

Company profile

Market position

SXTP company overview

SXTP company overview

Company profile

Market position

SXTP company overview

GoAI snapshot

Company profile

Market position

Financials

Financial snapshot

Valuation & yield

Profitability & efficiency

Financial health

Financial statements

Margin trends

Income trends

Earnings

EPS: actual versus estimate

Revenue: actual versus estimate

SXTP news

60 Degrees Pharmaceuticals Plans January 2027 Hospitalized Babesiosis Data Readout; Will Seek Pre-sNDA Meeting with FDA

60 Degrees Pharmaceuticals Announces Date for Hospitalized Babesiosis Study Interim Data Release and Key Opinion Leader Webinar

Reviewing Innoviva (NASDAQ:INVA) and 60 Degrees Pharmaceuticals (NASDAQ:SXTP)

60 Degrees Pharmaceuticals Announces Participation in H.C. Wainwright 28th Annual Global Investment Conference

60 Degrees Pharmaceuticals Announces Second Quarter 2026 Results

60 Degrees Pharmaceuticals, Inc. Announces Private Placement Priced At-the-Market Under Nasdaq Rules

Corporate actions

Corporate action history

SXTP peers

Continue in GoAI